



NDA 22425/S-021

**SUPPLEMENT APPROVAL**

sanofi-aventis U.S., LLC  
Attention: Nilda Ramos, MS  
Manager, Global Regulatory Affairs  
55 Corporate Drive  
Mailstop: 55D-225A  
Bridgewater, NJ 08807

Dear Ms. Ramos:

Please refer to your Supplemental New Drug Application (sNDA) dated January 24, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Multaq (dronedaron hydrochloride) 400 mg Tablets.

This "Prior Approval" supplemental new drug application provides for labeling revised as follows:

1. In HIGHLIGHTS/RECENT MAJOR CHANGES, items listed for more than one year have been removed.
2. Under ADVERSE REACTIONS/Postmarketing Experience/Cardiac, the following has been added:

Atrial flutter with 1:1 atrioventricular conduction has been reported very rarely.

3. The issue, revision, and copyright dates have been updated.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS**

We acknowledge receipt of your proposed REMS modification that included changes to the Medication Guide. Atrial flutter with 1:1 atrioventricular conduction appears to be a rare event in patients taking Multaq and is not addressed in the REMS. Therefore, we have determined that, at this time, the proposed changes to the Medication Guide are not needed, and a REMS modification is not necessary for Multaq to ensure that its benefits outweigh its risks. We will notify you if we become aware of new safety information and make a determination that a REMS modification is necessary.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of

labeling must be identical to the enclosed labeling with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(1)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Russell Fortney, Regulatory Project Manager, at (301) 796-1068.

Sincerely,

*{See appended electronic signature page}*

Mary Ross Southworth, Pharm.D.  
Deputy Director for Safety

Division of Cardiovascular and Renal Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

ENCLOSURE: Content of labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

MARY R SOUTHWORTH  
03/27/2013